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 Abstract
Objective: During the latency period of herpes simplex virus
type-1 (HSV-1), the virus can occasionally reactivate, travel
back to the eye and cause recurrent ocular disease. As this
condition arises from the ability of HSV-1 to produce a dor­
mant infection, effective medication to prevent the virus en­
ter a latent state should prevent it. In this study, we applied 
Echinacea polysaccharide (EP) fraction as prophylactic me­
diator for latency prevention.  Methods: In order to investi­
gate the protective properties of EP, we evaluated its immu­
nostimulatory functions on different immune aspects that
play important roles in latency prevention (particularly IFN­
- as one of the main indicators of cellular immunity and la­
tency). Finally, we assessed establishment of latency by de­
tection of thymidine kinase gene in trigeminal ganglia of 
BALB/c mice. Results: We demonstrated that EP promotes
immune response, leading to a reduced latency rate, and it 
has a promising effect on latency prevention.  Conclusion:
EP was able to exert an antiviral action on the development 
of recurrent HSV-1 disease when supplied prior to infec­
tion. Copyright © 2009 S. Karger AG, Basel 
 Introduction
Herpes simplex virus (HSV) infections are extremely 
common in humans and can occur at diverse sites with a 
wide range of symptoms, which range in severity from
unapparent to life-threatening encephalitis [1] . After the 
initial infection, HSV replicates in the skin or mucosal 
epithelium, then infects sensory nerves and is transport­
ed to the involved sensory ganglia. Here HSV establishes 
a life-long latent infection that is punctuated by periodic
reactivations [1, 2] . 
Following ocular infection, HSV-1 latency is estab­
lished in neurons of the trigeminal ganglion. Reactivated 
HSV-1 can travel back to the eye via axonal transport and 
be detected by culturing tear films (virus shedding). The 
scarring that occurs as a result of HSV ocular recurrence
is a major cause of corneal blindness  [3] . 
Despite of the seriousness of recurrent ocular herpes, 
there is no effective treatment for preventing the estab­
lishment of a latent infection and its consequent recur­
rences. Hence, development of medication for both pre­
vention and treatment of HSV infections has been the 
focus of research, as this is a cost-effective alternative to
chemical antiviral drugs  [4, 5]. 
Recently, an increased interest has been observed in
natural medicines that have immunotropic activity and
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which can increase cellular and humoral immunity
against pathogens  [6] . Echinacea purpurea extract has 
been used in prophylaxis and therapy of various viral in­
fections, mainly respiratory tract infections in animals 
and humans  [7] . 
Echinacea is perhaps best known for its reputed im­
munostimulating properties [8]. In vitro studies have
shown that Echinacea acts directly on a number of cell  
types, including natural killer cells  [9], polymorph nucle­
ar leukocytes [10] and macrophages  [11] .
Pharmacological investigations have shown immuno­
modulatory activities of cichoric acid, alkamides and 
polysaccharides from E. purpurea [12]. It appears that the 
immunostimulating effects of Echinacea result from
polysaccharides surrounding tissue cells which provide 
protection from pathogenic invasions  [12] .
E. purpurea polysaccharides (EPs) possess strong mac­
rophage-activating properties. Although they also have
some effect on B cell proliferation, their main targets  
seem to be macrophages  [13] . 
Intravenous treatment of mice with EP significantly
increased the survival rate in mice injected with lethal
doses of Candida albicans  or Listeria monocytogenes [14] .
The immune-stimulating properties of the polysac­
charide fractions from other  Echinacea species (E. angu­
stifolia) and other plants (Platycodon grandiflorum [15] 
and safflower petals) have also been proved  [16] .
In a previous study, we showed that EPs had a role in
reducing severe acute ocular disease of HSV-1 in a mouse 
model  [17]. In this study, EPs with in vivo anti-HSV-1 ac­
tivity were examined for their prophylactic effects on la­
tency establishment of HSV-1 in mice.
 Materials and Methods 
 Virus 
We extracted a virulent strain from a patient with signs of her­
petic encephalitis and confirmed this as being HSV-1 by using a 
HSV-1-specific monoclonal antibody [18]. In this study we used
the nonvirulent KOS strain of HSV-1 as a positive control. Stock 
viruses were grown and assayed on Vero cells in minimum essen­
tial medium containing 5% fetal bovine serum (Gibco BRL,  
Gaithersburg, Md., USA), 100 U/ml penicillin and 100  µ g/ml
streptomycin (Sigma-Aldrich, St. Louis, Mo., USA).
 Extract Characterization
EP fraction isolated from E. purpurea aerial parts was supplied
by Zardband Pharmaceutical Company (batch E.PC04-L002-82)
at a concentration of 20 mg/ml. Polysaccharides were precipitated
to create a polysaccharide-enriched extract which was controlled
for quality using thin-layer chromatography and densitometry
(data not shown). 
Polysaccharides have a molecular weight of 1.52!105 Da and
consist of rhamnose, arabinose, galactose and galacturonic acid
in a ratio of 0.5/3.5/2.5/11.25. 
Before use in experiments, EP was diluted in media and filter 
sterilized with 0.22 µ m syringe filters.
 Mice 
Female BALB/c mice, 4 to 5 weeks old, were purchased from
the Razi Vaccine and Serum Research Institute of Iran. Animals 
were handled in accordance with our institutional guidelines and 
were kept in animal housing under standard conditions. They had 
an average weight of 20 g. The mice were separated into 3 experi­
mental groups (10 mice per group) and the first group was intra­
peritoneally inoculated twice with 100 µl of inoculums contain­
ing 105 pfu of live KOS strain of HSV-1. The second group of mice, 
the negative control, was inoculated in the same manner with  
PBS. The last group of mice was inoculated with 100  µg of EP ex­
tract. All of the inoculations were performed on days 0 and 21.
 Delayed-Type Hypersensitivity 
Delayed-type hypersensitivity (DTH) response to HSV-1 was
tested 2 weeks after the last immunization in control and test
groups. UV-inactivated HSV-1 (KOS) with a titer of 105 pfu in 
5 µl of minimum essential medium (prior to UV inactivation) 
was subcutaneously injected into the right footpad as a test, and 
mock antigen (Vero cell extract) was injected into the left footpad 
as a negative control. The footpad thickness was measured in a 
blinded fashion with a Mauser dial caliper 24, 48 and 72 h later.
Results were expressed as a mean increase in footpad thickness at 
different hours following footpad injection over the pre-challenge 
thickness. Three mice per group were used, and the values ob­
tained were analyzed for statistical significance. 
The results were calculated according to the following for­
mula: 
Right footpad challenged with antigen – left footpad chal­
lenged with saline  ! 100/left footpad challenged with saline.
 Splenocyte Proliferation 
Splenocyte proliferation was measured 2 weeks after the last
inoculation for all the test and control groups. A final concentra­
tion of 2.5  ! 105 spleen cells/ml were exposed to 10 µ g/well phy­
tohemaglutinin (positive control) and inactivated HSV (specific 
antigen) for 5 days in a humidified tissue culture incubator (37°, 
5% CO2 ) [19] . 
The optimal concentrations of antigens or mitogens used to
stimulate cells were determined in preliminary studies: inacti­
vated virus as an antigen in 3 MOI. After incubation, 20 µ l of
MTT solution (5 mg/ml) was added to each well, and incubated 
again for 6 h. The crystals produced were dissolved in DMSO
(Merck, Darmstadt, Germany), and optical density was measured
(by the ELISA reader; Labsystem Multiskan MS) at a wavelength
of 540 nm. All assays were performed in triplicate. Results were 
expressed as stimulation index which was defined as the ratio of
the mean absorbance of antigen-stimulated cells to the mean of
unstimulated ones.
 IFN-- Assay
One of the immune parameters commonly used to assess the 
immunological impact is the production of IFN-- . IFN-- protein 
level in supernatants of stimulated spleen cells was measured by 
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Fig. 1. Delayed type hypersensitivity. The effect of KOS and EP on
the mean percent of DTH responses in BALB/c mice against in­
activated HSV virus. Each bar represents the mean percent of
DTH 8 standard error (error bar) for 3 mice per group. KOS and 
EP (Extract) groups are significantly different from the values vs. 
negative control group (p ! 0.05 by the Student’s t test).
ELISA using a quantitative sandwich enzyme immunoassay tech­
nique (Quantikine Kits; R&D Systems, Minneapolis, Minn., 
USA). The test was carried out according to the manufacturer’s 
instructions. Supernatants were harvested from wells for each 
group at 32 h post re-stimulation and they were diluted 1: 2 with 
the calibrator diluents before assaying to bring IFN-- levels with­
in the range of the standards. Standards, controls and samples 
were assayed at a wavelength of 450 and 550 nm for wavelength 
correction. Optical density (OD) was determined as the differ­
ence in OD between the 2 wavelengths, and the intensity of color 
reaction product was quantitated on a microplate reader (ELx800; 
BioTek Instruments, Winooski, Vt., USA). 
 A range of IFN-- dilutions was used to generate a standard 
curve to determine IFN-- concentration in the sample superna­
tant. The assay was performed in triplicate. The sensitivity of the 
tests was less than 2 pg/ml of IFN-  -. 
 Ocular Challenge 
Three weeks after the last immunization, all mice were anes­
thetized by intraperitoneal injection of 100 mg/kg ketamine 
(Parke-Davis, Pontypool, UK) and 10 mg/kg xylazine (Bayer, 
Bury St. Edmunds, UK) and then challenged with lethal HSV-1. 
Both corneas were lightly scarified using a 26 gauge needle. Then 
they were inoculated with 2 MLD50 (50% mouse lethal dose) of 
wild-type virus in a volume of 25  µ l PBS (5 ! 105.5 pfu/eye). The 
lids were held closed and gently rubbed for 30 s. All of the mice 
were monitored for 28 days after challenge. 
DNA Extraction from Trigeminal Ganglia 
At 28 days after challenge, mice were sacrificed and trigeminal 
ganglia were removed and rapidly frozen in liquid nitrogen. DNA 
was extracted from the tissue. Briefly, frozen tissue was chopped 
into small pieces and then suspended in 3 ml of DNA extraction 
buffer [10 mM Tris (pH 7. 5), 25 mM EDTA, 10 mM NaCl], 100  µl 
of 20% sodium dodecyl sulfate and 100  µg of proteinase K (20 
mg/ml) were added, and the treated tissue was digested at 56 ° over­
night. The DNA solution was purified 3 times with phenol-chlo­
roform and once more with chloroform and then precipitated  
with ethanol overnight. After centrifugation, it was finally dis­
solved in 20 µl of double distilled water  [20] . 
 Latency Assay 
In order to detect the presence of HSV-1 TK DNA in the gan­
glia, PCR was used to amplify 398 bp of the HSV-1TK gene with 
the primers for TK and adipsin gene (as an internal control) with 
a 176 bp PCR product described previously  [20] . 
 Statistical Analysis 
ANOVA test, at p  ^  0.05, was used for comparison of the stim­
ulation index of spleen splenocytes proliferation and DTH in an­
imal treated with EP and KOS. Student’s t test, at p  ! 0.05, was 
used for comparison of IFN-- production. Statistical differences 
in mouse survival among groups were analyzed using the Kaplan-
Meier test. 
 Results
 Delayed-Type Hypersensitivity 
In order to assess the effect of EP and KOS on the DTH 
responses, 3 mice/group were used. The results indicated 
a significant increase of DTH response after 24 and 48 h 
in both EP and KOS treated groups compared to the 
negative control ones. At 72 h after inoculation of antigen, 
both KOS and EP groups showed no significant differenc­
es in DTH responses compared to the controls (fig. 1).
 Splenocyte Proliferation 
In order to evaluate the effect of EP and KOS treatment 
on the proliferation of T lymphocytes, 3 mice/group were 
used. The mice were inoculated with KOS virus, PBS or 
treated with EP. The animals were sacrificed and the 
spleen cells were harvested. The splenocytes were acti­
vated in vitro by UV-inactivated HSV-1 KOS and evalu­
ated by MTT methods. A significant increase (p ^ 0.05) 
in the splenocyte proliferation was evident in KOS and 
EP treated groups over those of negative control ones, fol­
lowing stimulation of the spleen cells with UV-inactivat­
ed virus, as shown in table 1.
 IFN-- Assay 
As shown in figure 2, the spleen cells of EP-treated 
mice produced more IFN-- in the culture than did the 
cells from untreated mice. Values are averaged and statis­
tical analysis was carried out by a Student’s t test. 
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 Fig. 2. The effects of EP extract on mouse IFN- - production. 
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BALB/c mice (3 mice/treatment group) were treated as described
in ‘Materials and Methods’. Spleen cells of these mice were cul
tured for 32 h and the culture medium analyzed for IFN- - by
ELISA. Values are averaged and statistical analysis was done by a
Student’s t test. 
 Survival Analysis 
In order to evaluate the ability of KOS and EP treat­
ment to protect of mice following ocular HSV-1 challenge, 
10 mice from each group were used. Three weeks after the 
last immunization, the mice were challenged bi-ocularly 
with 5 ! 105.5  pfu/eye [2 MLD 50 (50% mouse lethal dose)] 
of wild-type strain of HSV-1. After lethal challenge, the 
mice were monitored for death. Ten mice out of 10 sur­
vived from the lethal challenge in KOS positive controls, 
while in the EP treated group only 1 death out of 10 was 
observed. In contrast, 9 out of 10 PBS-inoculated mice 
died following lethal challenge. The difference between 
the test group and mock inoculated group were statisti­
cally significant using Kaplan-Meier test (p ^ 0.05). The 
results indicated that the EP provided significant protec­
tion against ocular challenge and enhanced the survival 
time of HSV-1-infected mice [21] ( fig. 3 ). 
EP Effect on Establishment of Latent Infection 
The surviving mice challenged with 2 MLD50 HSV-1 
per eye were killed 28 days after infection. Trigeminal 
ganglia were removed and analyzed individually for the 
presence of latent HSV-1 gene. Latent genomes were de­
tected by PCR using oligonucleotide primers to the HSV­
1 TK gene. The results indicated that significant protec­
tion (x2 p = 0.05) against establishment of latency in EP 
groups had developed, as shown in table 2. 
Table 1. Spleen lymphocyte stimulation index 
Treatment (n = 3/group) Stimulation index 8 SD 
KOS (positive control) 1.9980.025a 
EP 2.3680.033a 
PBS (negative control) 0.9880.030 
a p < 0.05 vs. PBS control (ANOVA). 
Table 2. PCR results on extracted DNA from trigeminal ganglia 
of mice (x2 p=0.05) showed significant difference between EP and 
PBS groups 
Inoculum Mice, n Survival to 28 days PCR-
after challenge positive 
EP 10 9 4 
HSV-1 KOS 10 10 0 
 PBS 10 1 10 
    
  
 
   
 
 
 
   
  
  
 
 
 
 
 
 
 
 
Discussion
HSV infection is widespread. It is estimated that 70– 
90% of people over the age of 18 have antibodies to 
HSV-1 and/or HSV-2 and carry the latent virus, with ap­
proximately 25% showing clinical symptoms  [3] . Dur­
ing the life of a latently infected individual, the virus 
can occasionally reactivate, travel back to the eye and 
cause recurrent disease. A major cause of corneal scar­
ring is that induced by HSV-1 after reactivation from
latency  [3, 4] . 
In order to break the vicious circle of the latency, re­
currence and renewed latency of the virus, it is essential 
to induce a protective immune response for clearance of
the virus itself, since little or even no latency can then re­
occur in the case of primary or recurrent infection. The 
most important solution is therefore an immunostimula­
tory substance, whereby the virus is killed  [22, 23] . 
EP, which inhibits HSV-1 multiplication in vitro  [24] , 
was studied in a murine experimental model. Adult
BALB/c mice were inoculated with HSV-1 at their cor­
neas after abrasion. EP was administered twice as pro­
phylaxis. Our findings implied that the treatment with
EP as an immunostimulator, before lethal challenge, en­
hances the efficient immune responses leading to re­
duced viral multiplication in the eye. Subsequently, EP 
significantly affected and diminished the establishment 
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of a latent infection. As described before, we also con­
firmed in vivo the anti-herpetic effect of EP and showed 
that it significantly reduced the incidence and the sever­
ity of ocular disease with respect to untreated infected 
mice [17] . 
To our knowledge, in this study for the first time we
report that EP does induce T cell proliferation. This has
been attributed to macrophage activation to stimulate 
IFN-- production in association with the secondary ac­
tivation of T lymphocytes. The great production of IFN­
- by spleen cells from EP-treated mice suggested that in­
jection of EP would induce an appropriate Th1 immune 
response [22]. DTH and splenocyte proliferation results 
also confirmed immunity. 
On the other hand, it has been shown that IFN-- is one
of the major factors in latency prevention [20, 25, 26] .
Although there is ongoing controversy in the litera­
ture as to whether the immune-stimulating properties of
Echinacea are attributable to its polysaccharide compo­
nent, or whether it is the alkylamides that are responsible, 
this study once again verified the immunostimulatory ef­
fects of the polysaccharide component  [11] .
Numbers of active polysaccharides have been isolated 
from E. purpurea. Frequently, these include a 45-kDa 
polysaccharide fraction isolated from cultivated plants as
well as 2 neutral fucogalactoxyloglucans (10 and 25 kDa)
and a 75-kDa acid arabinogalactan from large-scale plant 
cell culture. It has been suggested that they synergize to
mediate a protective effect [27] .
When injected into mice, arabinogalactan was found 
to activate macrophages and was associated with an in­
creased production of TNF-a, IL-1 and interferons  [24] . 
Therefore, macrophage responses and consequent IFN--
induction to these polysaccharides can reduce latency 
rates. 
In comparison to the KOS group (as a positive con­
trol group), EP induced IFN-- with insignificant differ­
ence. Because of complete latency protection of KOS 
mice, it seems that EP has high prospective ability for 
improvement of its efficiency against latency in further 
studies. 
In conclusion, EP proved to exert an antiviral action
on the development of recurrent HSV-1 disease when 
supplied prior to infection. 
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